Not provided
Not provided
Not provided
Not provided
This is an early feasibility study. After the first 4 patients completed study activities, the investigator determined that this protocol is not the best way to test the study hypothesis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is tp evaluate the changes in stress induced Urethral Leak Point Pressures (LPP) and other urodynamic measurements in response to acute pudendal nerve stimulation (PNS) in patients with a pre-existing implanted urological neurostimulator stimulating the pudendal nerve.
Patients with a neurostimulator implanted at the pudendal nerve will be enrolled and undergo urodynamic testing. Before testing, study staff will provide an oral antibiotic (to reduce the risk of infection) and adjust the stimulation settings with a goal to increase urethral pressure from baseline by at lest 20cm H2O, without causing the patient discomfort/distress. These settings will be used throughout urodynamics. Before filling the bladder, a urethral pressure profile study will be completed 3 times with stimulation off, then 3 times with stimulation on. Leak point pressure (LPP) testing will then be completed. The patient's bladder will be filled following standard urodynamic testing protocol. Filling will be paused every 50-100mL to complete LPP assessment. Subjects will be asked to complete a light cough, medium cough, forceful cough, and Valsalva maneuver (in that order). Detrusor pressure will be measured at each event, and staff will document whether or not a leak was elicited. This will be completed with stimulation off, then with stimulation on, as the bladder is filled. Once the subject reports a strong urge to void, urethral pressure profile assessment will be completed again: 3 times with stimulation off, then 3 times with stimulation on. Once urodynamic testing is complete and the patient's bladder is emptied, a measurement of urethral pressure will be completed with stimulation off, then during 5 seconds of stimulation, then again with stimulation off.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Urodynamic testing with and without pudendal nerve stimulation | Other | The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with the stimulation sets turned off and then turned on. At the end of the UDT the settings will be returned to the previously set therapeutic values. The neuromodulation settings constitute the "dose" and can include the voltage/current amplitude, frequency, pulse width, on time/off time duration and electrode polarity assignments. These parameters are limited by the available ranges of the approved neurostimulation device and will be adjusted during the study by the principal investigator to stay within the safe and comfortable levels for each individual study subject. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Urodynamic testing with and without pudendal nerve stimulation | Diagnostic Test | A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra. |
| Measure | Description | Time Frame |
|---|---|---|
| Pulse Amplitude Triggering Patient Sensation at First Verbally Reported Sensation. | PNS final settings including: pulse amplitude, measured in mA, when subject first verbalizes sensation. Pulse amplitude is the amplitude of the electric pulses; measured in Milliamps (mA). This is a setting present on the neuromodulation device, it is not calculated. | After Visit 2 activities are complete. An average of 30 days after enrollment. |
| Pulse Frequency Triggering Patient Sensation at First Verbally Reported Sensation. | PNS final settings including: pulse frequencies, measured in Hz, when subject first verbalizes sensation. | After Visit 2 activities are complete. An average of 30 days after enrollment. |
| Pulse Width Triggering Patient Sensation at First Verbally Reported Sensation. | PNS final settings including: pulse widths, measured in µs, when the subject first verbalizes sensation. | After Visit 2 activities are complete. An average of 30 days after enrollment. |
| Identification of All Study-related Adverse Events | Safety and tolerability will be assessed in relation to the incidence of study related adverse events reported. | After Visit 2 activities are complete. An average of 30 days after enrollment. |
| Changes in Leak Point Pressure (LPP) Upon Acute PNS | Measurement of the change in LPP with acute PNS compared to without stimulation. To assess LPP, the urethral pressure increase will be calculated by subtracted pressure with and without stimulation at the "final setting". In cm water. | After Visit 2 activities are complete. An average of 30 days after enrollment. |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of Acute PNS on the Urethral Pressure Profile (UPP). | Measure the maximum urethral closure pressure with and without programmed pudendal nerve stimulation. In cm water. Urethral pressure profile is a test of the bladder neck, urethra, and urethral sphincters that is completed with urodynamic equipment. A small catheter is pulled at a constant rate from the bladder neck down the urethra to provide the functional length of the urethra and points of maximal urethral resistance at the urethral sphincter. It is a procedure used to measure the competency of the urethral sphincter (outflow resistance). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kenneth Peters, MD | Beaumont Hospital - Royal Oak | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beaumont Hospital - Royal Oak | Royal Oak | Michigan | 48073 | United States | ||
| Beaumont Hospital Royal Oak |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Urodynamic Testing With and Without Pudendal Nerve Stimulation | A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. UDT will be completed by filling the bladder and observing for urinary leakage. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Females with a neurostimulator implanted device
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Urodynamic Testing With and Without Pudendal Nerve Stimulation | A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. UDT will be completed by filling the bladder and observing for urinary leakage. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Pulse Amplitude Triggering Patient Sensation at First Verbally Reported Sensation. | PNS final settings including: pulse amplitude, measured in mA, when subject first verbalizes sensation. Pulse amplitude is the amplitude of the electric pulses; measured in Milliamps (mA). This is a setting present on the neuromodulation device, it is not calculated. | One subject did not have a pulse amplitude recorded. | Posted | Mean | Standard Deviation | mA | After Visit 2 activities are complete. An average of 30 days after enrollment. |
|
This was collected over approximately 5 weeks, from initial consent to subject study completion.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Urodynamic Testing With and Without Pudendal Nerve Stimulation | The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with stimulation turned off and on. At the end of the UDT the settings will be returned to the previously settings. Urodynamic testing with and without pudendal nerve stimulation: A urodynamic test (UDT) with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra. |
Not provided
Not provided
After the first 4 patients completed study activities, the investigator determined that this protocol is not the best way to test the study hypothesis due to uninterpretable data. Study was then terminated.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jennifer Giordano CRM | Beaumont Hosptials | 248-551-3517 | jennifer.giordano@corewellhealth.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 5, 2022 | May 11, 2023 | Prot_SAP_001.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Subjects who meet all eligibility criteria will be enrolled in the study and will undergo urodynamic testing with UPP.
Not provided
Not provided
Not provided
Not provided
|
| After Visit 2 activities are complete. An average of 30 days after enrollment. |
| Effect of Acute PNS on Max Cystometic Capacity. | Max cystometic capacity will be collected, with and without programmed PNS, the difference will be reported. In mL. | After Visit 2 activities are complete. An average of 30 days after enrollment. |
| Effect of Acute PNS on Post Void Residual. | Post void residual collected at end of UDT testing. Measured in mL. | After Visit 2 activities are complete. An average of 30 days after enrollment. |
| Royal Oak |
| Michigan |
| 48073 |
| United States |
| Participants |
|
| Age, Continuous | Mean | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
| Primary | Pulse Frequency Triggering Patient Sensation at First Verbally Reported Sensation. | PNS final settings including: pulse frequencies, measured in Hz, when subject first verbalizes sensation. | Posted | Mean | Standard Deviation | Hz | After Visit 2 activities are complete. An average of 30 days after enrollment. |
|
|
|
| Primary | Pulse Width Triggering Patient Sensation at First Verbally Reported Sensation. | PNS final settings including: pulse widths, measured in µs, when the subject first verbalizes sensation. | One participant did not have a pulse width recorded | Posted | Mean | Standard Deviation | µs | After Visit 2 activities are complete. An average of 30 days after enrollment. |
|
|
|
| Primary | Identification of All Study-related Adverse Events | Safety and tolerability will be assessed in relation to the incidence of study related adverse events reported. | Posted | Count of Participants | Participants | After Visit 2 activities are complete. An average of 30 days after enrollment. |
|
|
|
| Primary | Changes in Leak Point Pressure (LPP) Upon Acute PNS | Measurement of the change in LPP with acute PNS compared to without stimulation. To assess LPP, the urethral pressure increase will be calculated by subtracted pressure with and without stimulation at the "final setting". In cm water. | No leaks were noted in any of the four participants. | Posted | After Visit 2 activities are complete. An average of 30 days after enrollment. |
|
|
| Secondary | Effect of Acute PNS on the Urethral Pressure Profile (UPP). | Measure the maximum urethral closure pressure with and without programmed pudendal nerve stimulation. In cm water. Urethral pressure profile is a test of the bladder neck, urethra, and urethral sphincters that is completed with urodynamic equipment. A small catheter is pulled at a constant rate from the bladder neck down the urethra to provide the functional length of the urethra and points of maximal urethral resistance at the urethral sphincter. It is a procedure used to measure the competency of the urethral sphincter (outflow resistance). | Two participants did not complete. | Posted | Mean | Standard Deviation | cm water | After Visit 2 activities are complete. An average of 30 days after enrollment. |
|
|
|
| Secondary | Effect of Acute PNS on Max Cystometic Capacity. | Max cystometic capacity will be collected, with and without programmed PNS, the difference will be reported. In mL. | Not collected on any participants due to testing limitations. | Posted | After Visit 2 activities are complete. An average of 30 days after enrollment. |
|
|
| Secondary | Effect of Acute PNS on Post Void Residual. | Post void residual collected at end of UDT testing. Measured in mL. | Three participants did not have data collected. | Posted | Number | mL | After Visit 2 activities are complete. An average of 30 days after enrollment. |
|
|
|
| 0 |
| 4 |
| 0 |
| 4 |
| 0 |
| 4 |
Not provided
Not provided
Not provided
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |